The sizeable gap between winners and losers means due diligence is crucial
This feature explores spin-offs or de-mergers, looking at the rationale for them and how they have performed, and asks if they can be a promising hunting ground for investors. One of the UK’s largest recent spin-offs was GSK’s (GSK) demerger of its consumer healthcare division in 2022. GSK reportedly rebuffed a £50 billion offer from personal goods giant Unilever (ULVR) to buy the division, named Haleon (HLN) , in...